STOKE THERAPEUTICS, INC.
45 Wiggins Avenue
Bedford, MA 01730
May 26, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Office of Life Sciences |
| Re: | Stoke Therapeutics, Inc. |
Registration Statement on Form S-3
Filed May 20, 2022
File No. 333-265107
Via EDGAR - Acceleration Request
Requested Date: May 31, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Stoke Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| STOKE THERAPEUTICS, INC. | ||
| By: | /s/ Stephen J. Tulipano | |
| Stephen J. Tulipano | ||
| Chief Financial Officer | ||
| cc: | Edward M. Kaye, Chief Executive Officer |
Jonathan Allan, Deputy General Counsel
Stoke Therapeutics, Inc.
Robert A. Freedman, Esq.
Julia Forbess, Esq.
Fenwick & West LLP